MAY 1 1 2007

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL	Application Number	10/522,351	
	Filing Date	January 26, 2005	
FORM	First Named Inventor	Bruce J. Simon	
(to be used for all correspondence after initial filing)	Art Unit	1651	_
	Examiner Name	Susan Emily Fernandez	
otal Number of Pages in This Submission	Attorney Docket Number	5490E-000292/NPB	

		ENCLOSU	RES (check all t	hat apply)	
Fee Transmittal Form		☐ Drawing(s)			After Allowance Communication to Technology Center (TC)
Fee Attached		Licensing-re	elated Papers		Appeal Communication to Board of Appeals and Interferences
Amendment / Reply		Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final		Petition to Convert to a Provisional Application		*	Proprietary Information
Affidavits/dec	laration(s)		ttorney, Revocat Correspondence		Status Letter
Extension of Time	e Request	Terminal D	isclaimer		Other Enclosure(s) (please identify below):
Express Abandor	nment Request	☐ Request for Refund ☐ CD, Number of CD(s)			Form HDP 1449; 23 articles; return postcard
Information Disclo	sure Statement			-	
Certified Copy of Document(s)	Priority	Remarks The Commissioner is hereby authorized to charge any additional fees that may be required under 37 CFR 1.16 or 1.17 to Deposit Account No. 08-0750. A duplicate copy of this sheet is enclosed.			
Response to Miss			Account	10. 00-0750.	A duplicate copy of this sheet is enclosed.
Response to Parts under 3 1.52 or 1.53					
	SIGNA	TURE OF APP	LICANT, ATT	ORNEY, OF	RAGENT
Firm Name Harness, Dickey & Pierce, P.L.C.					
Signature					
Printed name David L. Suter					
Date May (, 2007 Reg. No. 30,692					
	CERTIFICATE OF TRANSMISSION/MAILING				

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	David L_Suter	Express Mail Label No.	EV 755 416 470 US (5/11/2007)
Signature	Subtite	Date	May 11, 2007
This self-self-self-self-self-self-self-self-	1 11 07 050 4 6 51 14 11 11 11 11 11 11 11		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Application No.:

10/522,351

Filing Date:

January 26, 2005

Applicant:

Bruce J. Simon

Group Art Unit:

1651

Examiner:

Susan Emily Fernandez

Title:

METHODS AND COMPOSITIONS FOR TREATING TISSUE

DEFECTS USING PULSED ELECTROMAGNETIC FIELD

STIMULUS

Attorney Docket:

5490E-000292/NPB

EBI 0891 (E-120)

Director of the United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant hereby submits an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS, AND OTHER INFORMATION

The patents, publications and other information requested to be considered by the Office (except unpublished U.S. patent applications) are listed on Form 1449 attached hereto.

II. COPIES

A. Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the Office; (iii) each unpublished U.S. application listed below in Section IV (i.e., including the specification, claims, and any drawing of the application, or that portion of the application which caused it to be listed, including any claims directed to that portion), except for such applications filed on or after June 30, 2003, pursuant to the Waiver of the Copy Requirement in 37 C.F.R. 1.98 (OG Notice dated

Serial No. 10/522,351

	be listed. B. Any patents, publications or other information which are listed on Form 1449 or on the copies of PTO-892, but which are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:
	U.S. Serial Number U.S. Filing Date
	C. This is a PCT application in the entry of the National Phase in the United States. A copy of the International Search Report is attached for the Examiner's information. The documents listed on the International Search report are listed on the attached Form 1449 for consideration by the Examiner and for listing on any patent resulting from this application. If the International Search report was from the US, EPO, or JPO search authorities, copies of these references should have been supplied to the USPTO under the trilateral agreement and are believed to be in the file of the above-identified application. (MPEP 1893.03(g).)
III.	CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)
	A. Except as may be indicated below in (B), all of the patents, publications or other information are in the English language (concise explanation not required).
	B. A concise explanation of the relevance of each patent, publication or other information listed that is not in the English language is as follows (see 37 C.F.R. § 1.98(a)(3)):
	1. See the attached foreign patent office communication from a counterpart foreign application:
	2. English translations are provided:
	3. Other:
	C. The following additional information is provided for the Examiner's consideration.

V.	CROSS REFE	RENCE TO R	ELATED APPLICA	ATION(S)	
	contain(s) subj bringing this(th	ect matter th ese) applicati	at may be related	llowing co-pending app d to the present applica liner's attention, Applicat 35 U.S.C. § 122.	ation. By
	Serial No	÷	Filing Date	Inventor(s)	
V .	THIS IDS IS BE	EING FILED L	<u>JNDER</u>		
	A. 🛛 37 C.F.R	. § 1.97(b): (c	heck <u>only</u> one box)	
	than a	continued pro		ate of a national applica on under § 1.53(d) (37 uired.	
	forth in §		international applic	entry of the national sta cation (37 C.F.R. § 1.97(I	
	1.97(b)(3 Office A under 3 1.97(e)	3)). No fee oction on the 7 C.F.R. § 1 below; or, if a	or certification is r merits has been .97(c) and see th no certification has	Action on the merits (37 required. In the event to issued, please consider e certification under 37 s been made, charge of as required by 37 C.F.R.	hat a first r this IDS C.F.R. § ur deposit
		nued examina		Action after the filing of .R. § 1.114. No fee or co	
	В. 37 С.F.R	. § 1.97(c): (c	heck <u>only</u> one box)	
	1.113, a		lowance under 37	al Office Action under 37 C.F.R. § 1.311, or an a	
		certification; F.R. § 1.17(p	·	the amount of \$180.00 i	s required
	2 □ Se	e the certifica	tion below No fee	e is required	

	C. 37 C.F.R. § 1.97(d):
	after the mailing date of either a Final Office Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, yet on or before payment of the issue fee.
	1. See the certification below. A fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
√I.	CERTIFICATION UNDER 37 C.F.R. § 1.97(e): (check only one box)
	The undersigned hereby certifies that:
	A. accommunication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(1)). See further statement under 37 C.F.R. 1.704(d) below in section VII, if applicable; or
	B. no item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(2)).
	C. some of the items of information were first cited in a communication from a foreign patent office. As to this information, the undersigned hereby certifies that each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS.
√II.	STATEMENT UNDER 37 C.F.R. 1.704(d)
	The undersigned hereby states that:
	☐ each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this IDS.

VIII. PAYMENT OF FEES (check only one box, if applicable)

A. A check in the amount of \$180.00 is enclosed for the above-identified fee.

B. Please charge Deposit Account No. 08-0750 in the amount of \$180.00 for the above-identified fee. A duplicate copy of this paper is attached.

Please charge any additional fees or credit any overpayment pursuant to 37 C.F.R. § 1.16 or § 1.17 to Deposit Account No. 08-0750.

The above references are being cited only in the interest of candor and without any admission that they constitute statutory prior art, contain matter which anticipates the invention, or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art. Furthermore, this Information Disclosure Statement shall not be construed as a representation that a search has been made.

If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 08-0750.

Respectfully submitted,

Dated: May 11, 2007

David L. Suter Reg. No. 30,692

By:

Harness, Dickey & Pierce, P.L.C. P.O. Box 828 Bloomfield Hills, Michigan 48303 (248) 641-1600

DLS/kq



FORM HDP-1440 (Based of orm PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 2

ATTORNEY DOCKET NO.	SERIAL NO.	
5490E-000292/NPB EBI 0891 (E-120)	10/522,351	
APPLICANT		
Bruce J. Simon		
FILING DATE	GROUP	
January 26, 2005	1651	

U.S. P	ATENT DO	CUMENTS				
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.		2005/0049640	03/03/2005	Gurtner et al.		

Ref. Desig.	Examiner's Initials	
1.		Amaral et al., Angiogenesis induced by electrical stimulation is mediated by angiotensin II and VEGF, Microcirculation 8, 57-67 (2001).
2.		Anderson et al., Electrical properties of wet collagen, Nature 218, 166-168 (1968).
3.		Bassett et al., Electrical behavior of cartilage during loading, Science 178, 982-983 (1972).
4.		Bassett et al., Generation of electric potentials by bone in response to mechanical stress, Science 137, 1063-1064 (1962).
5.		Bassett, The development and application of pulsed electromagnetic fields (PEMFs) for ununited fractures and arthrodeses, Orthop Clin North Am 15, 61-87 (1984).
6.		Becker et al., Bioelectric effects in tissue, Clin Orthop 43, 251-253 (1965).
7.		Borgens, Endogenous ionic currents traverse intact and damaged bone, Science 225, 478-482 (1984).
8.		Carmeliet et al., The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis, Thromb Haemost 86, 289-297 (2001).
9.		Chekanov et al., Angiogenesis in the latissimus dorsi muscle using different regimens of electrical stimulation and pharmaceutical support, Asaio J 46, 305-312 (2000).
10.		Cuevas et al., Electromagnetic therapeutic angiogenesis: the next step, Neurol Res 22, 349-350 (2000).
11.		Egginton et al., Selective long-term electrical stimulation of fast glycolytic fibres increases capillary supply but not oxidative enzyme activity in rat skeletal muscles, Exp Physiol 85.5, 567-574 (2000).
12.		Isner, Myocardial gene therapy, Nature 415, 234-239 (2002).
13.		Kalka et al., Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization, Proc Natl Acad Sci USA 97(7), 3422-3427 (2000).
14.		Kamihata et al., Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines, Circulation 104, 1046-1052 (2001).

Examiner:	Date Considered:



FORM HDP-1449 (Base on Early PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2 of 2

ATTORNEY DOCKET No.	SERIAL NO.
5490E-000292/NPB EBI 0891 (E-120)	
APPLICANT	
Bruce J. Simon	
FILING DATE	GROUP
January 26, 2005	1651

OTHE	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)				
Ref. Desig.	Examiner's Initials				
15.		Kanno et al., Establishment of a simple and practical procedure applicable to therapeutic angiogenesis, Circulation 99, 2682-2687 (1999).			
16.		Linderman et al., Development of an implantable muscle stimulator: measurement of stimulated angiogenesis and poststimulus vessel regression, Microcirculation 7, 119-128 (2000).			
17.		Lotke et al., Electromechanical properties in human articular cartilage, J Bone Joint Surg Am 56-A(5), 1040-1046 (1974).			
18.		Nehls et al., A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis, Microvasc Res 50, 311-322 (1995).			
19.		Shamos et al., Bioelectric effects in tissue, Clin Orthop 43, 254-255 (1965).			
20.		Shamos et al., Physical bases for bioelectric effects in mineralized tissues, Clin Orthop Relat Res 35, 177-188 (1964).			
21.		Sharrard et al., The treatment of fibrous non-union of fractures by pulsing electromagnetic stimulation, J Bone Joint Surg 64-B(2), 189-193 (1982).			
22.		Sharrard, A double-blind trail of pulsed electromagnetic fields for delayed union of tibial fractures, J Bone Joint Surg Br 72, 347-355 (1990).			
23.		Tomanek et al., Angiogenesis: new insights and therapeutic potential, Anat Rec 261, 126-135 (2000).			

Examiner:	Date Considered: